TY - JOUR
T1 - Lipoprotein (a)
T2 - An Update on a Marker of Residual Risk and Associated Clinical Manifestations
AU - Shah, Nishant P.
AU - Pajidipati, Neha J.
AU - McGarrah, Robert W.
AU - Navar, Ann Marie
AU - Vemulapalli, Sreekanth
AU - Blazing, Michael A.
AU - Shah, Svati H.
AU - Hernandez, Adrian F.
AU - Patel, Manesh R.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Lipoprotein (a) [Lp(a)] is a low-density, cholesterol-containing lipoprotein that differs from other low-density lipoproteins due to the presence of apolipoprotein(a) bound to its surface apolipoprotein B100. Multiple epidemiologic studies, including Mendelian Randomization studies, have demonstrated that increasing Lp(a) levels are associated with increased risk of heart disease, including atherosclerotic cardiovascular disease and calcific aortic stenosis. The risk associated with elevations in Lp(a) appears to be independent of other lipid markers. While the current treatment options for elevated Lp(a) are limited, promising new therapies are under development, leading to renewed interest in Lp(a). This review provides an overview of the biology and epidemiology of Lp(a), available outcome studies, and insights into future therapies.
AB - Lipoprotein (a) [Lp(a)] is a low-density, cholesterol-containing lipoprotein that differs from other low-density lipoproteins due to the presence of apolipoprotein(a) bound to its surface apolipoprotein B100. Multiple epidemiologic studies, including Mendelian Randomization studies, have demonstrated that increasing Lp(a) levels are associated with increased risk of heart disease, including atherosclerotic cardiovascular disease and calcific aortic stenosis. The risk associated with elevations in Lp(a) appears to be independent of other lipid markers. While the current treatment options for elevated Lp(a) are limited, promising new therapies are under development, leading to renewed interest in Lp(a). This review provides an overview of the biology and epidemiology of Lp(a), available outcome studies, and insights into future therapies.
UR - http://www.scopus.com/inward/record.url?scp=85083572077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083572077&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2020.03.043
DO - 10.1016/j.amjcard.2020.03.043
M3 - Review article
C2 - 32336532
AN - SCOPUS:85083572077
SN - 0002-9149
VL - 126
SP - 94
EP - 102
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -